If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
146.00    0.00 (0.00%)
Bid:
145.00
Ask:
147.00
Spread: 2.00 (1.379%)
Market Cap: £123.56m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Senior Management Appointments

11 Jul 2024 07:00

RNS Number : 9478V
Diaceutics PLC
11 July 2024
 

Diaceutics Makes Four Senior Management Appointments

VP Chief of Staff, VP of Human Resources, VP of Engagement Solutions and VP of Real-World Data

New roles will further strengthen management team and drive continued innovation, performance & growth at Diaceutics

 

Belfast and London, 11 July 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce four appointments to its executive team. These appointments are part of Diaceutics' commitment to strong governance and ensuring it has the structure in place to capitalise upon the growth in its market. The new Vice Presidents - Madeline Brown, Norma Thompson, Gosia Leitch, and Scott Phillips - bring a wealth of experience and expertise to their respective roles and will add significant strength to Diaceutics' leadership team and as it drives continued innovation, performance and growth.

Diaceutics CEO Ryan Keeling said, "Madeline, Norma, Gosia, and Scott are dynamic leaders whose extensive experience, vision and innovative approaches will be crucial in shaping Diaceutics' future performance and growth. As we continue to expand, their perspectives will be essential to helping us reach our full potential."

Madeline Brown, VP, Chief of Staff

Madeline Brown has been with Diaceutics since 2007, holding significant roles in finance and strategic project management. She will now lead the Chief Executive's Office, focusing on driving efficiencies and scalability.

Norma Thompson, VP of Human Resources

Norma Thompson joined Diaceutics in 2019 as Global Head of Human Resources. With over 30 years of experience, she brings extensive knowledge in HR management, talent development, and regulatory environments, essential for Diaceutics' global operations.

Gosia Leitch, VP of Engagement Solutions

Gosia Leitch has over 20 years of experience in diagnostics and pharma, including roles at Veracyte, Abbott, Qiagen, Bayer Healthcare and SC Johnson. She will drive engagement strategies connecting diagnostics with the broader healthcare ecosystem.

Scott Phillips, VP of Real-World Data

Scott Phillips brings over 12 years of experience in real-world data, product development, strategy consulting, and business development. Previously at Komodo Health and COTA Healthcare, he will enhance Diaceutics' data strategy and integration of real-world evidence.

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Enquiries:

Diaceutics PLC 

Ryan Keeling, Chief Executive Officer

Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison, Nick Harland, Kate Hanshaw 

Alma Strategic Communications

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon, Kieran Breheny

diaceutics@almastrategic.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZGMNRGDGDZM
Date   Source Headline
1st Sep 20217:00 amRNSPDMR Shareholding/Share Incentive Plan
31st Aug 20217:00 amRNSNotice of Investor Presentation
30th Jul 20214:54 pmRNSPDMR Shareholding/Share Incentive Plan
8th Jul 20217:00 amRNSTrading Update
1st Jul 20217:00 amRNSIssue of Share Options and PDMR Shareholdings
29th Jun 20214:56 pmRNSPDMR Shareholding/Share Incentive Plan
24th Jun 20217:00 amRNSNew Contract Wins
18th Jun 20217:00 amRNSPurchase of Shares and PDMR Shareholding
16th Jun 20217:00 amRNSCapital Markets Day and KPI Update
7th Jun 20216:23 pmRNSPDMR Shareholding/Share Incentive Plan
7th Jun 20217:00 amRNSNotice of Capital Markets Day
4th Jun 20217:00 amRNSPresenting data on COVID impact on cancer at ASCO
21st May 20211:49 pmRNSHolding(s) in Company
21st May 20217:00 amRNSChange of Adviser
19th May 20213:24 pmRNSResult of AGM
13th May 20217:00 amRNSLGC SeraCare Partnership
12th May 20215:58 pmRNSSale of Shares and PDMR Shareholding
5th May 20216:03 pmRNSHolding(s) in Company
4th May 20213:11 pmRNSSale of Shares and Director/PDMR Shareholding
30th Apr 202111:01 amRNSShare Incentive Plan
21st Apr 20217:00 amRNSNotice of AGM and posting of Annual Report
12th Apr 20217:00 amRNSNew Vice President of Operations in Asia
8th Apr 20219:49 amRNSTransfer of Shares and Director/PDMR Shareholding
7th Apr 20217:58 amRNSTransfer of Shares and Director/PDMR Shareholding
6th Apr 202111:12 amRNSIssue of Share Options/PDMR Shareholdings
1st Apr 20217:00 amRNSCOVID-19 Testing Data licensing agreement
30th Mar 20217:00 amRNSNew lease agreement and related party transaction
15th Mar 20217:00 amRNSFinal Results
8th Mar 20217:00 amRNSNotice of Results
4th Mar 202112:49 pmRNSNew Vice President of Finance appointment
21st Jan 20217:00 amRNSQuarterly media update
11th Jan 20219:56 amRNSHolding(s) in Company
11th Jan 20217:00 amRNSTrading update
22nd Dec 20207:01 amRNSDirectorate Change
22nd Dec 20207:00 amRNSDirectorate Change
10th Dec 20203:10 pmRNSHolding(s) in Company
17th Nov 20207:00 amRNSEuropean international award win
10th Nov 20204:32 pmRNSHolding(s) in Company
28th Oct 20207:00 amRNSCommercial launch of DXRX
7th Sep 20202:05 pmRNSSecond Price Monitoring Extn
7th Sep 20202:00 pmRNSPrice Monitoring Extension
7th Sep 202011:00 amRNSPrice Monitoring Extension
7th Sep 20207:00 amRNSHalf-year Report
27th Aug 20207:00 amRNSNotice of Results
22nd Jul 20207:00 amRNSNew contract win for DXRX platform
9th Jul 20207:00 amRNSHolding(s) in Company
8th Jul 20207:00 amRNSTrading update
6th Jul 20204:41 pmRNSSecond Price Monitoring Extn
6th Jul 20204:36 pmRNSPrice Monitoring Extension
3rd Jul 202010:43 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.